Remdesivir reduces Covid hospitalizations when given early, study shows
Gilead’s Covid-19 drug remdesivir appeared to reduce hospitalizations by 87% in high-risk patients diagnosed early in the disease in a new study, the company said Wednesday.
The new results, which were issued in a press release, could help shore up the perception that the medicine is effective. They also could boost hopes for the use of oral antiviral drugs being developed by drug companies including Pfizer and Merck to treat people in the early stages of Covid-19.
Read Original Article: Remdesivir reduces Covid hospitalizations when given early, study shows »
